Giorgio Ottaviani
InvestorOperating Partner at Versant Ventures
About
Operating Partner at Versant and SVP of Preclinical Development at the firm's Ridgeline Discovery Engine, with drug development expertise. He joined Ridgeline in 2018 from Roche, where he led DMPK-PD project leaders and headed non-clinical safety in Shanghai, and previously worked at Novartis and Merck-Serono. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Geneva and is a certified toxicologist (DABT).
Colleagues at Versant Ventures
Alex Mayweg
Managing Director at Versant Ventures
Alicia Levey
Venture Partner at Versant Ventures
Andrew Jefferson
Operating Partner at Versant Ventures
Ariel Kantor
Principal at Versant Ventures
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Managing Director at Versant Ventures
Bill Link
Investor at Versant Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures